Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Page 1
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10. Diabetes Care. 2015. PMID: 25758770 Free PMC article.

PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for

…
PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P …
Outcome measures for outpatient hypoglycemia prevention studies.
Beck RW, Kollman C, Xing D, Buckingham BA, Chase HP. Beck RW, et al. Among authors: chase hp. J Diabetes Sci Technol. 2011 Jul 1;5(4):999-1004. doi: 10.1177/193229681100500423. J Diabetes Sci Technol. 2011. PMID: 21880243 Free PMC article.
In outpatient studies designed to test such systems, CGM-measured glycemic indices will not only be important outcome measures of efficacy but, in certain cases, will be the only good outcome. This is especially true in short-term studies designed to reduce hypoglycemia si …
In outpatient studies designed to test such systems, CGM-measured glycemic indices will not only be important outcome measures of efficacy b …
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring.
Xing D, Kollman C, Beck RW, Tamborlane WV, Laffel L, Buckingham BA, Wilson DM, Weinzimer S, Fiallo-Scharer R, Ruedy KJ; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Xing D, et al. Diabetes Technol Ther. 2011 Mar;13(3):351-8. doi: 10.1089/dia.2010.0156. Epub 2011 Feb 7. Diabetes Technol Ther. 2011. PMID: 21299401 Free PMC article. Clinical Trial.
AIMS AND HYPOTHESIS: The optimal duration and frequency of short-term continuous glucose monitoring (CGM) to reflect long-term glycemia have not been determined. ...
AIMS AND HYPOTHESIS: The optimal duration and frequency of short-term continuous glucose monitoring (CGM) to reflect long-term …
Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Buckingham B, Miller K, Wolpert H, Xing D, Block JM, Chase HP, Hirsch I, Kollman C, Laffel L, Lawrence JM, Milaszewski K, Ruedy KJ, Tamborlane WV. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, et al. Among authors: chase hp. Diabetes Care. 2009 Nov;32(11):1947-53. doi: 10.2337/dc09-0889. Epub 2009 Aug 12. Diabetes Care. 2009. PMID: 19675206 Free PMC article. Clinical Trial.
Frequency of blood glucose meter monitoring and initial CGM use may help predict the likelihood of long-term CGM benefit in intensively treated patients with type 1 diabetes of all ages....
Frequency of blood glucose meter monitoring and initial CGM use may help predict the likelihood of long-term CGM benefit in intensive …
Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Tamborlane WV, Weinzimer S, Wolpert H. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, et al. Diabetes Care. 2009 Nov;32(11):2047-9. doi: 10.2337/dc09-0846. Epub 2009 Aug 12. Diabetes Care. 2009. PMID: 19675193 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate long-term effects of continuous glucose monitoring (CGM) in intensively treated adults with type 1 diabetes. ...
OBJECTIVE: To evaluate long-term effects of continuous glucose monitoring (CGM) in intensively treated adults with type 1 diabetes. . …
Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
Chase HP, Lutz K, Pencek R, Zhang B, Porter L. Chase HP, et al. J Pediatr. 2009 Sep;155(3):369-73. doi: 10.1016/j.jpeds.2009.03.012. Epub 2009 May 21. J Pediatr. 2009. PMID: 19464026 Clinical Trial.
CONCLUSIONS: Pramlintide reduced postprandial glucagon and glucose excursions and slowed gastric emptying in adolescents with type 1 diabetes, with no treatment-related adverse events. Long-term studies evaluating the efficacy and safety of pramlintide in adolescents are w …
CONCLUSIONS: Pramlintide reduced postprandial glucagon and glucose excursions and slowed gastric emptying in adolescents with type 1 diabete …
Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy.
Diabetes Research in Children Network Study Group; Weinzimer S, Xing D, Tansey M, Fiallo-Scharer R, Mauras N, Wysocki T, Beck R, Tamborlane W, Ruedy K. Diabetes Research in Children Network Study Group, et al. Pediatr Diabetes. 2009 Apr;10(2):91-6. doi: 10.1111/j.1399-5448.2008.00476.x. Epub 2008 Oct 20. Pediatr Diabetes. 2009. PMID: 19175899
Although many subjects and parents found CGM valuable, the declining usage over time underscores the need to develop new technologies and strategies to increase acceptance, effectiveness, and long-term use of these devices in youth with T1D....
Although many subjects and parents found CGM valuable, the declining usage over time underscores the need to develop new technologies and st …
Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes.
Scrimgeour L, Cobry E, McFann K, Burdick P, Weimer C, Slover R, Chase HP. Scrimgeour L, et al. Among authors: chase hp. Diabetes Technol Ther. 2007 Oct;9(5):421-8. doi: 10.1089/dia.2007.0214. Diabetes Technol Ther. 2007. PMID: 17931050
BACKGROUND: There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children. ...BMI z-scores showed a nonsignificant increase. CONCLUSIONS: The long-term use of CSII in pediatric patie …
BACKGROUND: There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin p …
Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus.
Garg SK, Anderson JH, Perry SV, Mackenzie T, Keith P, Jennings MK, Hansen MM, Chase HP. Garg SK, et al. Among authors: chase hp. Diabet Med. 1999 May;16(5):384-7. doi: 10.1046/j.1464-5491.1999.00066.x. Diabet Med. 1999. PMID: 10342337 Clinical Trial.
AIMS: To evaluate the long-term effectiveness of Humalog insulin in lowering post meal glucose excursions. ...
AIMS: To evaluate the long-term effectiveness of Humalog insulin in lowering post meal glucose excursions. ...
Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes.
Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, Chase HP. Garg SK, et al. Among authors: chase hp. Diabet Med. 1996 Jan;13(1):47-52. doi: 10.1002/(SICI)1096-9136(199601)13:1<47::AID-DIA999>3.0.CO;2-M. Diabet Med. 1996. PMID: 8741812 Clinical Trial.
The present prospective one-year randomized study was conducted to compare soluble human insulin, with a new rapid-acting human insulin analogue, lispro, with respect to postprandial glucose excursions, frequency of hypoglycaemic episodes, glucose control, and long-term sa …
The present prospective one-year randomized study was conducted to compare soluble human insulin, with a new rapid-acting human insulin anal …
14 results